|
|
Article: Wound Management Technologies (OTCBB- WNDM) Signs Biotech Agreement With Biocure S.r.l. of Milan, Italy.
- Article from:
- Diabetes Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Wound Management Technologies, Inc., (BULLETIN BOARD: WNDM) through its subsidiary, Wound Care Innovations, announced that it has reached an agreement with Biocure S.r.l. of Milan, Italy for the distribution of WNDM's patented molecular form of activated collagen, CellerateRx=AE (see also Diabetes).
CellerateRx is cleared by the FDA as a medical device for use on all acute and chronic wounds except for 3rd degree burns and is made in the USA. In the US alone, approximately 85% of lower extremity amputations are preceded by chronic diabetic foot wounds which lead to over 82,000 amputations annually with direct and indirect costs in the range of $2,500,000,000 to ...
Related newspaper, magazine, and journal articles:
|
|
Article: Wound Management Technologies Acquires Resorbable ...
PR Newswire;
October 1, 2009 ;
700+ words
... ... existing CellerateRx wound care products. Wound Management Technologies, through two subsidiaries ... factors. About Wound Management Technologies, Inc. Wound Management Technologies, through its subsidiary Wound Care Innovations, markets ...
|
|